Scientific Presentations at Society Meetings

Academy of Managed Care Pharmacy

American College of Cardiology

Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Gregson J, Pocock SJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the annual meeting of the American College of Cardiology, March 16-18, 2019, New Orleans, Louisiana.

Toth P, Granowitz C, Hull M, Philip S. Long-term statin persistence is poor among high-risk patients with baseline peripheral artery disease: a real-world administrative claims analysis of the Optum research database [abstract]. J Am Coll Cardiol. 2019;73:1744.

Wong ND, Fan W, Philip S, Granowitz C, Toth P. Burden of atherosclerotic cardiovascular disease risk in persons with elevated triglyceride levels according to statin use [abstract]. J Am Coll Cardiol. 2019;73:1763. 

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1445.

American Heart Association
Budoff MJ, Muhlestein JB, Bhatt DL, Le VT, May HT, Shaikh K, Shekar C, Kinninger A, Lakshmanan S, Roy S, Tayek J, Nelson JR. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy (EVAPORATE study) [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

Melendez GC, Medina-Hernandez D, Pflum AW, Xu V, Herrington DM. Purified eicosapentaenoic acid ameliorates cardiac fibrosis and tissue inflammation in spontaneously hypertensive rats [abstract]. Circulation. 2019;140(suppl 1):A13892.

Weintraub WS, Bhatt DL, Zhang Z, Dolman SF, Zhang C, Boden II WE, Bress AP, King JB, Steg PG, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl in REDUCE-IT [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

Spyropoulos J, Boutsalis G, Anderson D. Improving appropriate use of omega-3 fatty acids in primary care: success of online CME [abstract]. Circulation. 2019;140(suppl 1):A16351.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum S, Doyle R, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM. REDUCE-IT USA: results from the 3,146 patients drandomized in the United States [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

Sherratt SC, Mason RP. Contrasting effects of eicosapentaenoic and arachidonic acid on membrane cholesterol crystal formation under hyperglycemic conditions [abstract]. Circulation. 2019;140(suppl 1):A13936.

Wong ND, Fan W, Philip S, Toth PP, Granowitz C. Many statin treated persons with borderline triglyceride levels are at risk of ASCVD [abstract]. Circulation. 2019;140(suppl 1):A13771.

Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif, JC, Ballantyne CM. The primary results of the REDUCE-IT trial [abstract 19515]. Circulation. 2018;138:e752-e753.

Sherratt SC, Mason RP. Eicosapentaenoic acid, unlike other omega-3 fatty acids, inhibits membrane cholesterol crystalline domains under conditions of hyperglycemia [abstract]. Circ Res. 2019;125(suppl 1):A784.

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term statin persistence is poor among high-risk patients in a real-world administrative claims analysis [abstract]. Circulation. 2017;136(suppl 1):A15786.

Braeckman RA, Manku MS, Ballantyne CM, Stirtan WG, Soni PN. Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Circulation. 2012;126:A18549.

American Diabetes Association
Toth PP, Philip S, Hull M, Granowitz CB. Long-term statin persistence is poor among high-risk patients with baseline diabetes: a real-world administrative claims analysis. Diabetes. 2019;68(suppl 1):616P.

Pagidipati N, Navar A, Mulder H, Wojdyla DM, Philip S, Granowitz CB. Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trial. Diabetes. 2019;68(suppl 1):1472P.

Sherratt S, Mason RP. Eicosapentaenoic acid (EPA) inhibits human HDL oxidation in a concentration-dependent manner at a pharmacologic dose in vitro. Diabetes. 2019;68(suppl 1):612P.

Nichols G, Philip S, Granowitz CB, Reynolds K, Fazio S. Increased cardiovascular risk in patients with diabetes, statin-controlled LDL cholesterol, and residual hypertriglyceridemia [abstract]. Diabetes. 2018;67(suppl 1):1485P.

Fan W, Philip S, Granowitz CB, Toth PP, Wong ND. Prevalence and predictors of residual hypertriglyceridemia according to statin use in U.S. adults with diabetes [abstract]. Diabetes. 2018;67(suppl 1):332OR.

American Society for Preventive Cardiology
Bays HE, Ballantyne CM, Philip S, Juliano RA, Doyle RT, Granowitz CG.
The triglyceride-lowering effects of icosapent ethyl (pure eicosapentaenoic acid ethyl ester) correlate with reductions in ASCVD risk factors commonly found in hypertriglyceridemic patients.
Presented at: The American Society for Preventive Cardiology, July 27-29, 2018, Santa Ana Pueblo, NM. 

European Atherosclerosis Society
Mason RP, Sherratt SCR, Malinski T. Eicosapentaenoic acid inhibited oxidized HDL-induced loss of endothelial nitric oxide release as compared to fenofibrate or niacin in vitro. Presented at: The European Atherosclerosis Society Congress, May 5-8, 2018, Lisbon, Portugal.

Konishi T. Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging. Clin Cardiol. 2019;42(6):618-628.

Mason R, Sherratt S. Eicosapentaenoic Acid (EPA) Inhibits Human Low-Density Lipoprotein Oxidation in a Concentration- And Time-Dependent Manner at Pharmacologic Doses In Vitro [abstract EAS19-0568]. Atherosclerosis. 2019; in press.

Gordon Conference on Atherosclerosis
Dunbar RL, Copland C, Jiao L, Wang R, Wong K, Millar JS, Escobar M, Siri-Tarino P, Juliano RA. Eicosapentaenoic acid exposure lowers triglycerides without raising LDL-C by slowing TRL production and hastening LDL clearance in patients with residual triglyceridemia. Poster presented at the Gordon Conference on Atherosclerosis, June 16-21, 2019, Newry, Maine.

Dunbar RL, Copland C, Jiao L, Wang R, Wong K, Millar JS, Escobar M, Siri-Tarino P, Juliano RA. Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial. Poster presented at the Gordon Conference on Atherosclerosis, June 16-21, 2019, Newry, Maine.

Kern Lipid Conference
Abstracts are not published – approved to post to Amarin’s website
Juliano RA, Braeckman RA, Manku MS, Ballantyne CM, Doyle RT Jr, Soni PN, Stirtan WG. Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Presented at: The Kern Lipid Conference, August 3-4, 2015, Vail, Colorado.

PI|LIFESTYLE (Epidemiology and Prevention | Lifestyle and Cardiometabolic Health)
Robert RC, Liu L, Tsai MY, O'Connell TD, Shearer GC. Eicosapentaenoic acid is a strong predictor of risk for heart failure in the multi-ethnic study of atherosclerosis. Circulation . 2018;137:A026.

International Society for the Study of Fatty Acids and Lipids
Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of small dense LDL in a manner distinct from related fatty acids in vitro [poster]. Presented at: The Congress of the International Society for the Study of Fatty Acids and Lipids, Las Vegas, Nevada, May 27-31, 2018.

International Society for Pharmacoeconomics and Outcomes Research
Nichols GA, Reynolds K, Philip S, Granowitz C, Fazio S. The potential of electronic health record data to optimize recruitment efficiency in cardiovascular outcome trials [abstract PRM9]. Value Health. 2017;20:A312.

Nyandege A, Burudpakdee C, Philip S. Predictive modeling to assess predictors of treatment success and failure among combination statin therapy patients [abstract PRM20]. Value Health. 2014;17:A546.

National Lipid Association
Lee A, Kinninger A, Jayawardena E, Shekar C, Cherukuri L, Dailing C, Hamal S, Flores F, Budoff M, Nelson J. Relationship between lipid levels and coronary atherosclerotic plaque scores by coronary computed tomography angiography (CTA) in subjects with elevated triglycerides. J Clin Lipidol. 2019.

Case BC, Bress A, Kolm P, Philip S, Herrick J, Granowitz C, Toth P, Fan W, Wong N, Hull M, Weintraub W. The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. J Clin Lipidol. 2019.

Philip S, Fan W, Granowitz C, Toth P, Wong N. Prevalence of US adults with triglycerides ≥135 mg/dL: NHANES 2007-2014. J Clin Lipidol. 2019.

Cherukuri L, Shekar C, Kinninger A, Birudaraju D, Jayawardena E, Hamal S, Flores F, Tayek J, Roy S, Budoff M, Nelson J. Association between lipids and coronary atherosclerotic plaque characteristics. J Clin Lipidol. 2019.

Sherratt S, Mason R. Eicosapentaenoic acid, unlike arachidonic acid, maintains normal membrane structure and cholesterol distribution under conditions of hyperglycemia. J Clin Lipidol. 2019.

Cherukuri L, Shekar C, Kinninger A, Birudaraju D, Hamal S, Flores F, Tayek J, Roy S, Budoff M, Nelson J, Johanis A. Comparison of atherosclerotic plaque characteristics among normal and high triglycerides (TGs) patients. J Clin Lipidol. 2019; epub ahead of print.
https://www.lipidjournal.com/article/S1933-2874(19)30118-7/fulltext

Fan W, Philip S, Granowitz C, Toth P, Wong N. Prevalence and predictors of residual hypertriglyceridemia according to statin use in US adults [abstract 178]. J Clin Lipidol. 2018;12(2):530-531.

Hilleman D, Teply R, Packard K. Knowledge, perceptions, and patterns of fish oil use in cardiac patients [abstract 165]. J Clin Lipidol. 2018;12(2):552-553.

Nelson J, He L, Gill R, Dansinger M. Plasma EPA (eicosapentaenoic acid)/AA (arachidonic acid) ratio in patients with stage 5 chronic kidney disease: a novel, treatable target? [abstract 183]. J Clin Lipidol. 2018;12(2):553-554.

Nichols G, Granowitz C, Reynolds K, Philip S, Fazio S. The potential of electronic health record data to optimize recruitment efficiency in cardiovascular outcome trials [abstract 138]. J Clin Lipidol. 2017;11:796-797.

National Kidney Foundation
Szerlip HM, Vijay K, Ballantyne CM, Bays HE, Granowitz C, Doyle RT, Juliano RA, Philip S. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with persistent high triglycerides, EGFR <90 mL/min/1.73 m2, and diabetes mellitus [abstract 295]. Am J Kidney Dis.2018;71(4):589.

Vijay K, Szerlip HM, Ballantyne CM, Nelson JR, Granowitz C, Doyle RT, Juliano RA, Philip S. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with persistent high triglycerides, EGFR <90 mL/min/1.73 m2, and elevated high-sensitivity C-reactive protein =2.0 mg/L [abstract 317]. Am J Kidney Dis. 2018;71(4):594-595.

Obesity Society
Kedia AW, Lynch E. Omega-3 fatty acid treatment in an obese patient with hypertension and persistently elevated triglycerides despite statin therapy: reductions in triglycerides and low-density lipoprotein cholesterol and improvements in other lipid parameters following switch from omega-3 fatty acid ethyl esters to icosapent ethyl [abstract]. Presented at: the Annual Obesity Week meeting, November 2-7, 2015, Los Angeles, California.
Available online at: Page S154